Search Results - "Boxer, Geoffrey M"

Predicting Response to Radioimmunotherapy from the Tumor Microenvironment of Colorectal Carcinomas by EL EMIR, Ethaar, QURESHI, Uzma, DEARLING, Jason L. J, BOXER, Geoffrey M, CLATWORTHY, Innes, FOLARIN, Amos A, ROBSON, Mathew P, NAGL, Sylvia, KONERDING, Moritz A, PEDLEY, R. Barbara

“…Solid tumors have a heterogeneous pathophysiology, which directly affects antibody-targeted therapies. Here, we consider the influence of selected tumor…”
Get full text

Microdistribution of Targeted, Fluorescently Labeled Anti–Carcinoembryonic Antigen Antibody in Metastatic Colorectal Cancer: Implications for Radioimmunotherapy by Fidarova, Elena F., El-Emir, Ethaar, Boxer, Geoffrey M., Qureshi, Uzma, Dearling, Jason L.J., Robson, Mathew P., Begent, Richard H.J., Trott, Klaus R., Pedley, R. Barbara

“…Purpose: Most radioimmunotherapy studies on radiolabeled antibody distribution are based on autoradiographic and radioluminographic data, which provide a lack…”
Get full text

Sustained Tumor Regression of Human Colorectal Cancer Xenografts Using a Multifunctional Mannosylated Fusion Protein in Antibody-Directed Enzyme Prodrug Therapy by SHARMA, Surinder K, PEDLEY, R. Barbara, BEGENT, Richard H. J, CHESTER, Kerry A, BHATIA, Jeetendra, BOXER, Geoffrey M, EL-EMIR, Ethaar, QURESHI, Uzma, TOLNER, Berend, LOWE, Helen, MICHAEL, N. Paul, MINTON, Nigel

“…Purpose: Antibody-directed enzyme prodrug therapy (ADEPT) requires highly selective antibody-mediated delivery of enzyme to tumor. MFE-CP, a multifunctional…”
Get full text

Significant Therapeutic Efficacy with Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer by Vassileva, Vessela, Rajkumar, Vineeth, Mazzantini, Mario, Robson, Mathew, Badar, Adam, Sharma, Surinder, Årstad, Erik, Hochhauser, Daniel, Lythgoe, Mark F, Kinghorn, Jane, Boxer, Geoffrey M, Pedley, Rosmund Barbara

“…Despite extensive efforts to improve the clinical management of patients with colorectal cancer, approved treatments for advanced disease offer limited…”
Get full text

Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate by PEDLEY, R. Barbara, HILL, Sally A, BOXER, Geoffrey M, FLYNN, Aiden A, BODEN, Robert, WATSON, Rebecca, DEARLING, Jason, CHAPLIN, David J, BEGENT, Richard H. J

“…Solid tumors have a heterogeneous pathophysiology, which has a major impact on therapy. Using SW1222 colorectal xenografts grown in nude mice, we have shown…”
Get full text

Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice by El-Emir, Ethaar, Boxer, Geoffrey M., Petrie, Ingrid A., Boden, Robert W., Dearling, Jason L.J., Begent, Richard H.J., Pedley, R. Barbara

“…Combretastatin A-4 phosphate (CA4-P) is an antivascular agent which inhibits tumour blood flow. The effects of CA4-P were studied at 1 and 24 h in colorectal…”
Get full text

Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake by Dearling, Jason L.J, Flynn, Aiden A, Qureshi, Uzma, Whiting, Stephen, Boxer, Geoffrey M, Green, Alan, Begent, Richard H.J, Pedley, R. Barbara

“…Abstract Introduction Radioimmunotherapy (RIT) has been shown to be more effective against solid tumor micrometastases, possibly due to an inverse relationship…”
Get full text

Analysis of the Regional Uptake of Radiolabeled Deoxyglucose Analogs in Human Tumor Xenografts by Dearling, Jason L.J, Flynn, Aiden A, Sutcliffe-Goulden, Julie, Petrie, Ingrid A, Boden, Robert, Green, Alan J, Boxer, Geoffrey M, Begent, Richard H.J, Pedley, R. Barbara

“…It has been shown in vitro that the cell uptake of (18)F-FDG, a tracer of glucose metabolism, increases under hypoxia. This is consistent with increased…”
Get full text

Synergy between vascular targeting agents and antibody-directed therapy by Pedley, R Barbara, El-Emir, Ethaar, Flynn, Aiden A, Boxer, Geoffrey M, Dearling, Jason, Raleigh, James A, Hill, Sally A, Stuart, Sam, Motha, Reeya, Begent, Richard H J

“…Tumor heterogeneity necessitates the use of combined therapies. We have shown that combining antibody-directed therapy with antivascular agents converts a…”
Get more information

Enhancement of Antibody-directed enzyme prodrug Therapy in colorectal xenografts by an antivascular agent by PEDLEY, R. B, SHARMA, S. K, BOXER, G. M, BODEN, R, STRIBBLING, S. M, DAVIES, L, SPRINGER, C. J, BEGENT, R. H. J

“…The irregular nature of solid tumor vasculature produces a heterogeneous distribution of antibody-targeted therapies within the tumor mass, which frequently…”
Get full text

The Nonuniformity of Antibody Distribution in the Kidney and its Influence on Dosimetry by Flynn, Aiden A., Pedley, R. Barbara, Green, Alan J., Dearling, Jason L., El-Emir, Ethaar, Boxer, Geoffrey M., Boden, Robert, Begent, Richard H. J.

“…Flynn, A. A., Pedley, R. B., Green, A. J., Dearling, J. L., El-Emir, E., Boxer, G. M., Boden, R. and Begent, R. H. J. The Nonuniformity of Antibody…”
Get full text

Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents by PEDLEY, R. B, BODEN, J. A, BODEN, R, BOXER, G. M, FLYNN, A. A, KEEP, P. A, BEGENT, R. H. J

“…Radioimmunotherapy (RIT) does not readily eradicate common solid tumors and therefore requires augmentation by complementary therapies that do not increase…”
Get full text

A model‐based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection by Flynn, Aiden A., Green, Alan J., Pedley, R. Barbara, Boxer, Geoffrey M., Dearling, Jason, Watson, Rebecca, Boden, Robert, Begent, Richard H. J.

“…BACKGROUND The effectiveness of radioimmunotherapy (RIT) is known to depend on at least six factors: total absorbed dose and pattern of delivery,…”
Get full text

Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images by FLYNN, Aiden A, BOXER, Geoffrey M, BEGENT, Richard H. J, PEDLEY, R. Barbara

“…Antibody-directed cancer therapy has achieved encouraging responses despite poor localisation in tumour. This discrepancy may be attributed to heterogeneity of…”
Get full text

A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model by Flynn, A A, Green, A J, Boxer, G M, Casey, J L, Pedley, R B, Begent, R H

“…Radioimmunotherapy of cancer employs an antitumour antibody to carry a radionuclide selectively to deposits of cancer. Conventional dose estimates, based on…”
Get more information

Gestational and nongestational trophoblastic tumors distinguished by DNA analysis by Fisher, R A, Newlands, E S, Jeffreys, A J, Boxer, G M, Begent, R H, Rustin, G J, Bagshawe, K D

“…In three patients in whom a diagnosis of gestational trophoblastic tumor was possible on the basis of pathology and elevated levels of serum human chorionic…”
Get more information

Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images by Flynn, A A, Pedley, R B, Green, A J, Boxer, G M, Boden, R, Begent, R H

“…The biological effect of radioimmunotherapy (RIT) is most commonly assessed in terms of the absorbed radiation dose. In tumor, conventional dosimetry methods…”
Get more information

Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model by Pedley, R B, Begent, R H, Boden, J A, Boxer, G M, Boden, R, Keep, P A

“…Radioimmunotherapy (RIT) is hampered clinically by poor tumour localization of antibody. In order to enhance localization we have investigated the concomitant…”
Get more information

Localization of CEA messenger RNA by in situ hybridization in normal colonic mucosa and colorectal adenocarcinomas by Abbasi, A M, Chester, K A, MacPherson, A J, Boxer, G M, Begent, R H, Malcolm, A D

“…Carcinoembryonic antigen (CEA) mRNA expression was studied in 14 cases of normal colorectal mucosa and colonic adenocarcinomas using in situ hybridization with…”
Get more information

Selective uptake of toxic nucleoside (125IUdR) by resistant cancer by Bagshawe, K D, Sharma, K, Southall, P J, Boden, J A, Boxer, G M, Patridge, T A, Antoniw, P, Pedley, R B

“…We report uptake of a thymidine analogue 125-Iodine-5-iodo-2'-deoxyuridine (125IUdR) by nude mice bearing human xenografts of choriocarcinoma or colonic…”
Get more information